Clinical characteristics of progressive relapsing multiple sclerosis

Multiple Sclerosis

Volumn 10, Issue 4, 2004, Pages 451-454

  Tullman, Mark J ^a   Oshinsky, R J ^b   Lublin, F D ^a   Cutter, G R ^c  

^a MOUNT SINAI HOSPITAL   (United States)

^b Solvay Pharmaceuticals Inc   (Netherlands)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Clinical characteristics; Disability; Multiple sclerosis; Progressive relapsing; Relapses

Indexed keywords

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; COHORT ANALYSIS; DISABILITY; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE EXACERBATION; FEMALE; HUMAN; MALE; MEDICAL RECORD; MULTIPLE SCLEROSIS; RATING SCALE; RELAPSE; RETROSPECTIVE STUDY; SPINAL CORD DISEASE; SYMPTOMATOLOGY; TIME;

ADULT; COHORT STUDIES; DISABILITY EVALUATION; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MEDICAL RECORDS; MIDDLE AGED; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; RETROSPECTIVE STUDIES; SPINAL CORD DISEASES;

EID: 4344584070     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1191/1352458504ms1059oa     Document Type: Article

References (22)

1. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996; 46: 907-11.
2. Andersson PB, Waubant E, Gee L, Goodkin DE. Multiple sclerosis that is progressive from the time of onset: clinical characteristics and progression of Disability. Arch Neurol 1999; 56: 1138-42.
3. Kremenchutzky M, Cottrell D, Rice G, Hader W, Baskerville J, Koopman W et al. The natural history of multiple sclerosis: a geographically based study. 7. Progressive-relapsing and relapsing-progressive multiple sclerosis: a re-evaluation. Brain 1999; 122: 1941-50.
4. Oshinsky RJ, Elfont RM, Lublin FD. Incidence and clinical characteristics of the progressive-relapsing form of MS. Neurology 1998; 50: A209.
5. Jacobs LD, Wende KE, Brownscheidle CM, Apatuff B, Coyle PK, Goodman A et al. A profile of multiple sclerosis: the New York State Multiple Sclerosis Consortium. Mult Scler 1999; 5: 369-76.
6. Confavreux C, Vukusic S, Moreau T, Adeleine P. Relapses and progression of disability in multiple sclerosis. N Engl J Med 2000; 343: 1430-38.
7. Bashir K, Whitaker JN. Clinical and laboratory features of primary progressive and secondary progressive MS. Neurology 1999; 53: 765-71.
8. Confavreux C, Aimard G, Devic M. Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients. Brain 1980; 103: 281-300.
9. Cottrell DA, Kremenchutzky M, Rice GP, Koopman WJ, Hader W, Baskerville J et al. The natural history of multiple sclerosis: a geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis. Brain 1999; 122: 625-39.
10. McDonnell GV, Hawkins SA. Clinical study of primary progressive multiple sclerosis in Northern Ireland, UK. J Neurol Neurosurg Psychiatry 1998; 64: 451-54.
11. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med 2000; 343: 938-52.
12. Thompson AJ, Polman CH, Miller DH, McDonald WI, Brochet B, Filippi M et al. Primary progressive multiple sclerosis. Brain 1997; 120:1085-96.
13. Weinshenker BG. Progressive forms of MS: classification streamlined or consensus overturned? Lancet 2000; 355: 162-63.
14. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444-52.
15. Weinshenker BG, Bass B, Rice GP, Noseworthy J, Carriere W, Baskerville J et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 1989; 112: 133-46.
16. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 1998; 352: 1498-504.
17. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS. Lancet 1998; 352: 1491-97.
18. Hartung HP, Gonsette R, Konig N, Kwiecinski H, Guseo A, Morrissey SP et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 2002; 360: 2018-25.
19. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996; 39: 285-94.
20. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995; 45: 1268-76.
21. Lublin FD, Baier M, Cutter G. Effect of relapses on development of residual deficit in multiple sclerosis. Neurology 2003; 61: 1528-32.
22. Fischer JS, Rudick RA, Cutter GR, Reingold SC. The Multiple Sclerosis Functional Composite Measure (MSFQ: an integrated approach to MS clinical outcome assessment. National MS Society Clinical Outcomes Assessment Task Force. Mult Scler 1999; 5: 244-50.